A Bourdoncle

A Howell

A Hurtado

A Lipton

A Mackay

AM Warri

B Thurlimann

BB Rasmussen

BG Rowan

BW O’Malley

C Dati

CD Clyne

CK Osborne

CM Chan

D Greenbaum

DM Harvell

DM Lonard

E A Lien

E Myers

EM Berns

FJ Fleming

G Hudelist

G Mellgren

G Sabnis

H Iwase

H Mouridsen

HJ List

I Shin

J Bonneterre

J Geisler

J M Dixon

J Zhou

JM Harvey

JS Annicotte

L L Haugan Moi

LA Martin

LC Murphy

LD Read

LH Wang

M Dowsett

M Hauglid Flågeng

M Lippman

MP Fereshteh

MW Pfaffl

NP Bates

P E Lønning

P Puigserver

PL Xu

R Jakesz

R Safi

RC Coombes

RC Wu

RJ Santen

RX Song

S Bautista

S Masamura

SL Anzick

SQ Kuang

T Bouras

VC Jordan

VN Kristensen

W R Miller

WR Miller

English

PubMed

Background: Acquired resistance to endocrine therapy in breast cancer is poorly understood. Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity.Methods: We examined the expression levels of nuclear receptor co-regulators, the orphan nuclear receptor liver receptor homologue-1 and HER-2/neu growth factor receptor using real-time RT-PCR before and after 13–16 weeks of primary medical treatment with the aromatase inhibitors anastrozole or letrozole.Results: mRNA expression of the steroid receptor co-activator 1 (SRC-1) and peroxisome-proliferator-activated receptor γ co-activator-1α (PGC-1α) was correlated (P=0.002), and both co-activators increased during treatment in the patient group as a whole (P=0.008 and P=0.032, respectively), as well as in the subgroup of patients achieving an objective treatment response (P=0.002 and P=0.006). Although we recorded no significant change in SRC-3/amplified in breast cancer 1 level, the expression correlated positively to the change of SRC-1 (P=0.002). Notably, we recorded an increase in HER-2/neu levels during therapy in the total patient group (18 out of 26; P=0.016), but in particular among responders (15 out of 21; P=0.008).Conclusion: Our results show an upregulation of co-activator mRNA and HER-2/neu during treatment with aromatase inhibitors. These mechanisms may represent an early adaption of the breast cancer cells to oestrogen deprivation in vivo

Flågeng, M Hauglid

Moi, L L Haugan

Dixon, J M

Geisler, J

Lien, E A

Miller, W R

Lønning, P E

Mellgren, G

Edinburgh Research Explorer

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

Crossref

A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.

Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.

The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 24: 8167–8175 Anzick

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768454

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

Abstract

Similar works

Full text

Available Versions

Edinburgh Research Explorer

Crossref